Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
| ▸ | TPH1 | P17752 | 1/20 | 0.32 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5199239 | 0.88 | UPP1 (0.44) | UPP1 | |
| SCHEMBL7260719 | 0.87 | MEN1 (0.35) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MEN1 | |
| SCHEMBL7255075 | 0.87 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5198534 | 0.86 | UPP1 (0.38) | SMN1; SMN2ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL5200101 | 0.86 | SMN1; SMN2 (0.34) | SMN1; SMN2ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL7256071 | 0.86 | ALDH1A1 (0.32) | SMN1; SMN2ALDH1A1IDH1MEN1KMT2A | |
| SCHEMBL7254871 | 0.85 | ALDH1A1 (0.32) | SMN1; SMN2ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL5199124 | 0.85 | UPP1 (0.37) | UPP1 | |
| SCHEMBL598947 | 0.85 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1PDE3BPDE3AHPGD | |
| SCHEMBL5197944 | 0.84 | MEN1 (0.34) | ALDH1A1KDM4EMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4342543-B1 | TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12569464-B2 | Protein-protein interaction inducing technology | ARVINAS OPERATIONS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2010030858-A1 | 4'-ALLENE-SUBSTITUTED NUCLEOSIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20090274686-A1 | NUCLEOSIDE PHOSPHONATE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| US-7307065-B2 | 2′-Fluoronucleosides | EMORY UNIVERSITY (US) | 2007-12-11 | — | — | US | disclosed |
| US-20070225249-A1 | 2'-Fluoronucleoside phosphonates as antiviral agents | COCRYSTAL PHARMA, INC. | 2007-09-27 | — | — | US | disclosed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| US-20040254141-A1 | 2'-Fluoronucleosides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-16 | — | — | US | disclosed |
| EP-0736015-B1 | ANTIVIRAL 2,4-PYRIMIDINDIONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RES INST CHEM TECH (KR) | 2001-03-07 | — | — | EP | disclosed |
| US-5747500-A | VIRICIDES FOR AIDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1998-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225249-A1 | 2'-Fluoronucleoside phosphonates as antiviral agents | PCNA, DUT, TYMP | SMN1; SMN2 3796/4885ALDH1A1 3923/4885PDE3B 3901/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | SMN1; SMN2 3245/4885ALDH1A1 3454/4885PDE3B 4846/4885 |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | SMN1; SMN2 512/4885ALDH1A1 2448/4885PDE3B 1839/4885 |
| US-20040254141-A1 | 2'-Fluoronucleosides | NSUN2, PNP, FDPS | SMN1; SMN2 2590/4885ALDH1A1 3361/4885PDE3B 3001/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | SMN1; SMN2 2370/4885ALDH1A1 3506/4885PDE3B 4703/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | SMN1; SMN2 2818/4885ALDH1A1 3895/4885PDE3B 4558/4885 |
| US-12569464-B2 | Protein-protein interaction inducing technology | STUB1, MDM2, XIAP | SMN1; SMN2 2934/4885ALDH1A1 4507/4885PDE3B 4688/4885 |
| US-20090274686-A1 | NUCLEOSIDE PHOSPHONATE DERIVATIVES | ENTPD5, PNP, TYMP | SMN1; SMN2 3825/4885ALDH1A1 1105/4885PDE3B 662/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | SMN1; SMN2 2142/4885ALDH1A1 2777/4885PDE3B 4857/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | SMN1; SMN2 2811/4885ALDH1A1 1263/4885PDE3B 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.